Search results for " phase III trial"

showing 1 items of 1 documents

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…

2013

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…

OncologyMaleIndolesPyridinesSettore MED/06 - Oncologia MedicaSU11248MedizinPiperazineslaw.inventionchemistry.chemical_compoundRandomized controlled triallawClinical endpointSunitinibTreatment Failureregorafenib; gastrointestinal stromal tumours; imatinib and sunitinibGastrointestinal Neoplasmseducation.field_of_studyGiSTSunitinibKITAge-related aspects of cancer Quality of hospital and integrated care [ONCOL 2]General MedicineMiddle AgedSurvival RateBenzamidesImatinib MesylateFemaleADJUVANT IMATINIBTYROSINE KINASE INHIBITORColorectal NeoplasmsLife Sciences & Biomedicinemedicine.drugGROWTH-FACTORmedicine.medical_specialtyGastrointestinal Stromal TumorsPopulationMESYLATEAntineoplastic AgentsIMATINIBArticleMECHANISMSMedicine General & InternalDouble-Blind MethodTranslational research [ONCOL 3]General & Internal MedicineRegorafenibInternal medicineMANAGEMENTmedicineHumansPyrroleseducationProtein Kinase InhibitorsAgedScience & TechnologyGASTROINTESTINAL STROMAL TUMOURSimatinib and sunitinibMUTATIONSbusiness.industryPhenylurea CompoundsGIST regorafenib imatinib sunitinib phase III trialSurgeryClinical trialImatinib mesylatePyrimidineschemistryregorafenibbusinessRESISTANCE
researchProduct